Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TRDA | US
0.78
4.79%
Healthcare
Biotechnology
30/06/2024
04/10/2024
17.07
16.88
17.20
16.68
Entrada Therapeutics Inc. a biotechnology company develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide antibody and enzyme-based programs. The company's lead therapeutic candidates which include ENTR-601-44 and ENTR-601-45 which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501 an intracellular thymidine phosphorylase enzyme replacement therapy which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701 which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research develop manufacture and commercialize ENTR-701. The company was formerly known as CycloPorters Inc. and changed its name to Entrada Therapeutics Inc. in October 2017. Entrada Therapeutics Inc. was incorporated in 2016 and is headquartered in Boston Massachusetts.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Smallcap (300M - 2B USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
53.0%1 month
56.6%3 months
65.0%6 months
59.8%5.45
3.33K
1.42
0.15
0.11
2.13
0.86
-
96.87M
635.00M
635.00M
-
56.42
-
421.20
32.80
16.11
9.35
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.90
Range1M
3.92
Range3M
4.71
Rel. volume
0.64
Price X volume
1.70M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 8.27 | 698.29M | 0.85% | n/a | 0.11% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
CureVac N.V | CVAC | Biotechnology | 3.02 | 679.69M | 0.67% | n/a | 10.37% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 9.61 | 677.91M | -1.84% | n/a | 0.92% |
Mereo BioPharma Group plc | MREO | Biotechnology | 4.4 | 676.95M | 2.56% | n/a | 7.83% |
ATXS | ATXS | Biotechnology | 11.87 | 669.77M | 2.06% | n/a | 1.67% |
ANNX | ANNX | Biotechnology | 6.29 | 664.56M | -2.02% | n/a | 8.36% |
OLMA | OLMA | Biotechnology | 11.6 | 664.29M | -3.73% | n/a | 0.86% |
Humacyte Inc | HUMA | Biotechnology | 5.44 | 650.86M | -4.39% | n/a | -63.37% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.13 | 0.76 | Expensive |
Ent. to Revenue | 0.86 | 3,674.48 | Cheaper |
PE Ratio | 5.45 | 38.01 | Cheaper |
Price to Book | 1.42 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 64.97 | 74.67 | Par |
Debt to Equity | 0.15 | -1.82 | Expensive |
Debt to Assets | 0.11 | 0.26 | Cheaper |
Market Cap | 635.00M | 3.73B | Emerging |